NASDAQ: AZN

Explore the latest insights on NASDAQ: AZN and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of NASDAQ: AZN’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

European Commission Revokes Hansoh's Aumolertinib Marketing Authorization – EU Approval Reversed Seven Months After Grant in TAGRISSO Data‑Protection Dispute
CompanyDrug

European Commission Revokes Hansoh’s Aumolertinib Marketing Authorization – EU Approval Reversed Seven Months After Grant in TAGRISSO Data‑Protection Dispute

Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that the European Commission (EC) has revoked the marketing authorization for Aumolertinib, just seven months after its EU approval in February 2026.…

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

Atavistik Bio Strikes CVRM Collaboration with Roche – USD 70 Million Upfront, up to USD 1.9 Billion in Milestones for Allosteric Small‑Molecule Discovery

Atavistik Bio Strikes CVRM Collaboration with Roche – USD 70 Million Upfront, up to USD 1.9 Billion in Milestones for Allosteric Small‑Molecule Discovery

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Major Pharma Companies Pledge Support for 250,000 Genomes Sequencing Project

CompanyDrug

Sanofi and AstraZeneca Receive FDA Approval for RSV Prevention Treatment Beyfortus

CompanyDrug

Chile Expands Financial Coverage for AbbVie’s RSV Prophylaxis Synagis

Company

Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results

CompanyDrug

AstraZeneca and Daiichi Sankyo’s Enhertu Gains New Indication Approval in China for HER2-Low Breast Cancer

CompanyDeals

LianBio Secures Clinical Supply Agreement with AstraZeneca for SHP2 Inhibitor Trial

CompanyDrug

AstraZeneca’s Dapagliflozin and Metformin Combo Approved by China’s NMPA for Type 2 Diabetes

Company

AstraZeneca Weighs Spinning Off China Business to Shield Against Geopolitical Tensions

Show More